Business
Organigram Extends Innovation Investment with Phylos
Expanded agreement expected to deliver Organigram enhanced operational security, priority access ...
About this update from Organigram Global Inc.
[{"type":"text","content":"Organigram Extends Innovation Investment with Phylos\n\n\n .bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignt { vertical-align: top }\n \n\n\n\n Expanded agreement expected to deliver Organigram enhanced operational security, priority access to selected genetics, and a robust seed pipeline through 2030\n \n\n\n Key Highlights:\n \n\n\n\n US$3 million investment accelerates Organigram’s innovation strategy, providing access to next-generation genetics and strengthening its leadership in seed-based cultivation.\n \n\n Industry-leading seed pipeline, with 30 new, next-generation genetics delivered twice annually through 2030, supporting innovation for recreational and medical markets.\n \n\n Five-year exclusive rights secured for Organigram’s chosen cannabis genetics in international markets, with flexibility to add new territories as global expansion continues.\n \n\n\n\n\n Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada’s #1 cannabis company by market share\n \n 1\n \n , today announced the expansion of its innovation investment in Phylos Bioscience Inc. (“Phylos”), securing Organigram’s position as a leader in seed-based cannabis genetics. Through an amended loan and product agreement, Organigram gains priority access to Phylos’ autoflower genetics pipeline, including preferential economic terms and long-term rights in its international markets, establishing a foundation for product differentiation and growth in recreational and medical markets.\n \n\n\n Operational Security Through a Long-Term Seed Pipeline\n \n\n\n According to Borna Zlamalik, SVP Innovation & International R&D at Organigram, “Seed-based cultivation has become a key advantage of Organigram’s cultivation strategy, giving us unprecedented consistency, scalability, and economic benefit. Our follow-on investment in Phylos secures the portfolio breadth of next-generation cultivars required to meet the needs of Organigram's consumers and patients.”\n \n\n\n International Exclusivity for Genetics\n \n\n\n Under the amended product agreeme...